Latest News and Press Releases

BOTHELL, WA--(Marketwired - Nov 16, 2016) - Marina Biotech, Inc. (OTCQB: MRNA) today announced that it has signed a definitive merger agreement with IthenaPharma Inc., a company focused on the...

BOTHELL, WA--(Marketwired - Jun 2, 2016) - Marina Biotech, Inc. (OTCQB: MRNA), a leading nucleic acid-based drug discovery and development company focused on rare diseases, today announcd that J....

BOTHELL, WA--(Marketwired - May 17, 2016) - Marina Biotech, Inc. (OTCQB: MRNA), a leading nucleic acid-based drug discovery and development company focused on rare diseases, today reported recent...

BOTHELL, WA, and BAAR, SWITZERLAND--(Marketwired - May 3, 2016) - Marina Biotech, Inc. (OTCQB: MRNA), a leading nucleic acid-based drug discovery and development company focused on rare diseases...

BOTHELL, WA--(Marketwired - May 3, 2016) - Marina Biotech, Inc. (OTCQB: MRNA), a leading nucleic acid-based drug discovery and development company focused on rare diseases announced that they have...

BOTHELL, WA--(Marketwired - Mar 31, 2016) - Marina Biotech, Inc. (OTCQB: MRNA), a leading nucleic acid-based drug discovery and development company focused on rare diseases, today reported year-end...

BOTHELL, WA--(Marketwired - Mar 16, 2016) - Marina Biotech, Inc. (OTCQB: MRNA), a leading nucleic acid-based drug discovery and development company focused on rare diseases, announced today that...

NEW YORK, NY and BOTHELL, WA--(Marketwired - Mar 15, 2016) - Microlin Bio, Inc. (OTCQB: MICB), a development stage biotechnology company focused on the development of microRNA based therapeutics...

BOTHELL, WA--(Marketwired - Feb 18, 2016) - Marina Biotech, Inc. (OTCQB: MRNA), a leading nucleic acid-based drug discovery and development company focused on rare diseases announced today that...

BOTHELL, WA--(Marketwired - Feb 17, 2016) - Marina Biotech, Inc. (OTCQB: MRNA), a leading nucleic acid-based drug discovery and development company focused on rare diseases, announced today that...